Q1 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
Broad pipeline of novel medicines continued to progress in Q1
Approvals
PluvictoⓇ
Vijoice®1
US: mCRPC post-taxane
US: PROS
3
INNOVATION
Neuroscience
Cardio-Renal
Oncology
Immunology
Readouts and publications
Tislelizumab
JDQ443
Ph3 Gastric cancer (primary OS endpoint)
Encouraging early data (Ph1b KontRASt-01)
ScemblixⓇ
BeovuⓇ
JP: CML 3L
EU: DME
Tafinlar+Mekinist CN: NSCLC with BRAF V600 mutation
Submissions
Designations
Iptacopan
Tislelizumab
ScemblixⓇ
Tislelizumab
AimovigⓇ
EU: NSCLC, 2L ESCC
CN: Migraine
1. Post quarter event
Selected milestones
17 Investor Relations | Q1 2022 Results
China Breakthrough in C3G
US Orphan in 1L nasopharyngeal cancer
JP priority review in CML 3L
Major study starts
T-Charge T
PHE885
Ph2 in Multiple Myeloma
ZolgensmaⓇ
Ph3 SMA IT (STEER)
✓ NOVARTIS | Reimagining MedicineView entire presentation